Why the study?
Does furosemide >80 mg/day increase the risk of all-cause death or HF hospitalization in patients with chronic stable heart failure compared to ≤80 mg/day?
Does furosemide >80 mg/day increase the risk of all-cause death or HF hospitalization in patients with chronic stable heart failure compared to ≤80 mg/day?
Higher maintenance doses of furosemide (>80 mg/day) are independently associated with worse long-term outcomes in chronic stable heart failure, particularly in euvolemic patients.
BACKGROUND: Prognostic implications of diuretics dose are not completely understood. We aim to study the association between diuretic doses and long-term prognosis in patients with chronic stable heart failure (HF). METHODS AND RESULTS: We conducted a retrospective cohort study of 244 patients followed at an outpatient HF clinic. Admission criteria were clinical stability in the previous 3 months and optimized medical therapy. Demographic characteristics, clinical, and laboratory parameters were recorded. Patients were followed for 2 years and the outcome was defined as all-cause death or hospital admission due to HF worsening. Patients on ≤ 80 mg furosemide were compared with those on higher doses. Patients were grouped according to furosemide dose (≤ 80 mg and >80 mg/d) and according to volemia as assessed by the sodium retention score: <3 (euvolemia) versus ≥ 3 (hypervolemia). Patients on higher diuretic doses (n = 79) were older, more hypervolemic, and more symptomatic. Patients on >80 mg furosemide had a higher risk of death or hospital admission (hazard ratio [HR]: 2.07, 95% confidence interval [CI]: 1.37-3.1). For each 40-mg furosemide tablet, there was a 67% increase in risk of an adverse outcome within 2 years. The increase in risk was independent of other variables crudely associated with prognosis. Among euvolemic patients, those on ≤ 80 mg/d furosemide performed better than those on higher doses. Among hypervolemic patients, the diuretic dose had no prognostic implications. CONCLUSIONS: Higher diuretic doses associated strongly and independently with adverse long-term outcome in chronic HF. Possibly, in euvolemic patients, efforts should be made to reduce diuretic dose.
No takes yet. Share an insight, caveat, or question.
Martins et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: